PAVmed to Present at the 20th Annual Needham Healthcare Conference
April 08 2021 - 9:30AM
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”
or “PAVmed”), a highly differentiated, multi-product,
commercial-stage medical technology company, today announced that
Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer
will present a corporate update at the 20th Annual Needham
Healthcare Conference on April 15, 2021 at 8:00 AM EDT.
To access the live webcast of the presentation,
please click here. A replay will be available following the
presentation and can be accessed in the Investor Relations section
of the PAVmed website.
About PAVmedPAVmed Inc. is a
highly differentiated, multi-product, commercial-stage medical
technology company employing a unique business model designed to
advance innovative products to commercialization rapidly and with
less capital than the typical medical device company. This
proprietary model enables PAVmed to pursue an expanding pipeline
strategy with a view to enhancing and accelerating value creation
while seeking to further expand its pipeline through relationships
with its network of clinician innovators at leading academic
centers. PAVmed’s diversified product pipeline addresses unmet
clinical needs encompassing a broad spectrum of clinical areas with
attractive regulatory pathways and market opportunities. Its four
operating divisions include GI Health (EsoGuard® Esophageal DNA
Test, EsoCheck® Esophageal Cell Collection Device, and EsoCure™
Esophageal Ablation Device with Caldus™ Technology), Minimally
Invasive Interventions (CarpX® Minimally Invasive Device for Carpal
Tunnel Syndrome), Infusion Therapy (PortIO™ Implantable Intraosseus
Vascular Access Device and NextFlo™ Highly Accurate Disposable
Intravenous Infusion Set), and Emerging Innovations (non-invasive
laser-based glucose monitoring, pediatric ear tubes, and mechanical
circulatory support). For more information, please visit
www.pavmed.com, follow us on Twitter, connect with us on LinkedIn,
and watch our videos on YouTube. For more information on our
majority owned subsidiary, Lucid Diagnostics Inc., please visit
www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on
LinkedIn. For detailed information on EsoGuard, please visit
www.EsoGuard.com and follow us on Twitter, Facebook and
Instagram.
Forward-Looking StatementsThis
press release includes forward-looking statements that involve
risks and uncertainties. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements,
based upon the current beliefs and expectations of PAVmed’s
management, are subject to risks and uncertainties, which could
cause actual results to differ from the forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things, volatility in the price of PAVmed’s common
stock, Series W Warrants and Series Z Warrants; general economic
and market conditions; the uncertainties inherent in research and
development, including the cost and time required advance PAVmed’s
products to regulatory submission; whether regulatory authorities
will be satisfied with the design of and results from PAVmed’s
preclinical studies; whether and when PAVmed’s products are cleared
by regulatory authorities; market acceptance of PAVmed’s products
once cleared and commercialized; our ability to raise additional
funding and other competitive developments. PAVmed has not yet
received clearance from the FDA or other regulatory body to market
many of its products. The Company has been monitoring the COVID-19
pandemic and its impact on our business. The Company expects the
significance of the COVID-19 pandemic, including the extent of its
effect on the Company’s financial and operational results, to be
dictated by, among other things, the success of efforts to contain
it and the impact of actions taken in response. New risks and
uncertainties may arise from time to time and are difficult to
predict. All of these factors are difficult or impossible to
predict accurately and many of them are beyond PAVmed’s control.
For a further list and description of these and other important
risks and uncertainties that may affect PAVmed’s future operations,
see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as the same may be updated in Part II, Item 1A, “Risk
Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after
its most recent Annual Report. PAVmed disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
Contacts:InvestorsMike HavrillaDirector of
Investor Relations(814) 241-4138JMH@PAVmed.com
MediaShaun O’NeilChief Commercial Officer(518)
812-3087SMO@PAVmed.com
Katie GallagherLaVoieHealthScience(617)
792-3937PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Sep 2024 to Oct 2024
PAVmed (NASDAQ:PAVM)
Historical Stock Chart
From Oct 2023 to Oct 2024